Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

February 28, 2006

Study Completion Date

December 31, 2006

Conditions
Ovarian CancerPrimary Peritoneal Carcinoma
Interventions
DRUG

Å6 subcutaneous injection

Trial Locations (24)

24014

Carilion Gynecologic Oncology Associates, Roanoke

29601

Gynecologic-Oncology Research and Development, LLC, Greenville

30912

Medical College of Georgia Dept. of OB/GYN, Saint Agusta

32804

Florida Hospital Cancer Institute, Orlando

35233

University of Alabama, Birmingham, Birmingham

37403

Chattanooga GYN Oncology, Chattanooga

40202

University of Louisville JG Brown Cancer Center, Louisville

43210

OSU College of Medicine, Columbus

44718

Gabrail Cancer Center, Canton

46260

St. Vincent Gyn-Onc, Indianapolis

46617

Northern Indiana Cancer Research Consortium, South Bend

60521

Gynecologic Oncology, Hinsdale

63110

Barnes Jewish Hospital, St Louis

70115

Hematology & Oncology Specialists, New Orleans

73190

University of Oklahoma College of Medicine, Oklahoma City

78234

Brooke Army Medical Center, Fort Sam Houston

80010

University of Colorado Cancer Center, Aurora

85222

Desert Oasis Cancer Center, Casa Grande

90033

USC Keck School of Medicine Women's and Childrens Hospital, Los Angeles

92121

Scripps Cancer Center, San Diego

92668

University of California Irvine Medical Center, Orange

93710

California Oncology of the Central Valley, Fresno

95817

UC Davis Health System, Sacramento

96859

Tripler Army Medical Center, Honolulu

All Listed Sponsors
lead

Ångstrom Pharmaceuticals

INDUSTRY

NCT00083928 - Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels | Biotech Hunter | Biotech Hunter